Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic, Wavi Collaborate on Dementia

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Under an agreement announced on Monday, Wavi will apply its bioinformatics expertise to SomaLogic's proprietary proteomics assays.

Additionally, the two companies will plan two clinical studies in dementia that combines Wavi's electroencephalogram-based biomarkers and SomaLogic's blood-based protein biomarkers.

"Our mission is pre-symptomatic detection leading to early diagnosis enabling timely treatment of cognitive ailments," Stephen Onody, president and CEO of Wavi, said in a statement.

Financial and other terms of the deal were not disclosed.

The deal is the second in the past week announced by SomaLogic. Last week, the Boulder, Colo.-based company said it would provide New England Biolabs specific aptamer-based reagents for nucleic acid amplification and PCR products.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.